{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:01:32Z","timestamp":1782903692617,"version":"3.54.5"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>There is a high level of public and professional interest related to potential safety issues of the COVID-19 vaccines; however, no serious adverse cardiovascular events were reported in phase 3 randomized controlled trials of their safety and efficacy. Moreover, none of the case series from the United States (US) of these potential complications have been population-based.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To estimate the reporting rates of myocarditis and pericarditis in the US using the Vaccine Adverse Event Reporting System (VAERS), and to assess if these adverse events were disproportionally reported among the different COVID-19 vaccines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, setting, and participants<\/jats:title><jats:p>All cases of myocarditis and pericarditis from VAERS reported up to July 28, 2021.<\/jats:p><\/jats:sec><jats:sec><jats:title>Exposure<\/jats:title><jats:p>Single-dose Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccinations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcomes and measures<\/jats:title><jats:p>Reporting rates were computed by dividing the total number of cases of myocarditis and pericarditis (combined) by the total number of vaccine doses administered. Disproportionality analyses were performed to evaluate disproportional reporting of myocarditis and pericarditis for the Ad26.COV2.S and mRNA-1273 vaccines vs. the BNT162b2 mRNA vaccine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>By July 28, 2021, 1392, 699, and 68 cases of myocarditis or pericarditis had been reported out of 1.91, 1.38, and 1.33 million administered doses of the BNT162b2 mRNA, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines, respectively. Median times to event were 3 days, 3 days, and 9 days for the BNT162b2 mRNA, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines. The reporting rates for myocarditis or pericarditis were 0.00073 (95% confidence interval, 95% CI 0.00069\u20130.00077), 0.00051 (95% CI 0.00047\u20130.00055), and 0.00005 events per dose (95% CI 0.00004\u20130.00006) for the BNT162b2 mRNA, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines, respectively. Myocarditis and pericarditis were disproportionally reported following the BNT162b2 mRNA vaccine when compared with the other vaccines, using both disproportionality measures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and relevance<\/jats:title><jats:p>We found reporting rates of myocarditis and pericarditis to be less than 0.1% after COVID-19 vaccination. Rates were highest for the BNT162b2 mRNA vaccine, followed by the mRNA-1273 and Ad26.COV2.S, respectively. However, the reporting rates of myocarditis and pericarditis secondary to vaccination remains less common than those seen for SARS-CoV-2 infection.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1210007","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T08:26:30Z","timestamp":1700814390000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines"],"prefix":"10.3389","volume":"10","author":[{"given":"Manan","family":"Pareek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Polverino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian Hay","family":"Kragholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","article-title":"2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC)Endorsed by: the European association for cardio-thoracic sur","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1056\/NEJMcp1404070","article-title":"Clinical practice. Acute pericarditis","volume":"371","author":"LeWinter","year":"2014","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0140-6736(11)60648-X","article-title":"Myocarditis","volume":"379","author":"Sagar","year":"2012","journal-title":"Lancet (London, England)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1161\/CIRCULATIONAHA.113.001531","article-title":"Good prognosis for pericarditis with and without myocardial involvement: results from a multicenter, prospective cohort study","volume":"128","author":"Imazio","year":"2013","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.hrthm.2020.05.001","article-title":"Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management","volume":"17","author":"Siripanthon","year":"2020","journal-title":"Hear Rhythm"},{"key":"B6","doi-asserted-by":"publisher","first-page":"n1635","DOI":"10.1136\/bmj.n1635","article-title":"COVID-19: should we be worried about reports of myocarditis and pericarditis after mRNA vaccines?","volume":"373","author":"Wise","year":"2021","journal-title":"Br Med J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1\u20132a trial of Ad26.COV2.S COVID-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/jamacardio.2021.2821","article-title":"Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines","volume":"6","author":"Shay","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3390\/vaccines10050722","article-title":"Risk of myocarditis and pericarditis among young adults following mRNA COVID-19 vaccinations","volume":"10","author":"Alami","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"938322","DOI":"10.3389\/fimmu.2022.938322","article-title":"Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: new insights from the vaccine adverse event reporting system","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1080\/14760584.2022.2100765","article-title":"Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States","volume":"21","author":"Hatziantoniou","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"B14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1016\/j.vaccine.2023.03.054","article-title":"Real-life safety profile of mRNA vaccines for COVID-19: an analysis of VAERS database","volume":"41","author":"Laurini","year":"2023","journal-title":"Vaccine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1016\/j.vaccine.2023.06.023","article-title":"Post-authorization safety surveillance of ad.26.COV2.S vaccine: reports to the vaccine adverse event reporting system and v-safe, February 2021\u2013February 2022","volume":"41","author":"Woo","year":"2023","journal-title":"Vaccine"},{"key":"B17","first-page":"1","article-title":"Myocarditis","author":"Wu","year":"2021","journal-title":"BMJ best Pract"},{"key":"B18","first-page":"1","article-title":"Pericarditis","author":"Baruah","year":"2021","journal-title":"BMJ best Pract"},{"key":"B19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00428-017-2107-1","article-title":"Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease","volume":"470","author":"Pilero","year":"2017","journal-title":"Virchows Arch"},{"key":"B20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3389\/fphar.2017.00305","article-title":"Campania preventability assessment committee (Italy): a focus on the preventability of non-steroidal anti-inflammatory drugs\u2019 adverse drug reactions","volume":"8","author":"Sessa","year":"2017","journal-title":"Front. Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4103\/0976-500X.184777","article-title":"A case of figurate urticaria by etanercept","volume":"7","author":"Sessa","year":"2016","journal-title":"J Pharmacol Pharmacother"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1517\/14740338.2015.1067301","article-title":"Suspected adverse reactions to contrast media in campania region (Italy): results from 14 years of post-marketing surveillance","volume":"14","author":"Sessa","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"B23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14740338.2016.1221397","article-title":"Campania region (Italy) spontaneous reporting system and preventability assessment through a case-by-case approach: a pilot study on psychotropic drugs","volume":"15","author":"Sessa","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"B24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/14740338.2016.1226280","article-title":"Campania preventability assessment committee: a focus on the preventability of the contrast media adverse drug reactions","volume":"15","author":"Sessa","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"B25","article-title":"Israel Examining heart inflammation cases in people who received pfizer COVID shot","volume":"1","year":"2021","journal-title":"Internet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1016\/j.vaccine.2021.05.016","article-title":"U.S. population-based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines","volume":"39","author":"Gubernot","year":"2021","journal-title":"Vaccine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1016\/j.vaccine.2021.05.087","article-title":"Myocarditis following COVID-19 mRNA vaccination","volume":"39","author":"Mouch","year":"2021","journal-title":"Vaccine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1161\/CIRCULATIONAHA.121.056038","article-title":"In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine","volume":"144","author":"Muthukumar","year":"2021","journal-title":"Circulation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1161\/CIRCULATIONAHA.121.055913","article-title":"Myocarditis after BNT162b2 and mRNA-1273 vaccination","volume":"144","author":"Larson","year":"2021","journal-title":"Circulation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.121.055891","article-title":"Myocarditis temporally associated with COVID-19 vaccination","volume":"144","author":"Rosner","year":"2021","journal-title":"Circulation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1016\/j.jcmg.2021.06.003","article-title":"A series of patients with myocarditis following SARS-CoV-2 vaccination with mRNA-1279 and BNT162b2","volume":"14","author":"Dickey","year":"2021","journal-title":"JACC. Cardiovasc. Imaging"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1001\/jama.289.24.3283","article-title":"Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel","volume":"289","author":"Halsell","year":"2003","journal-title":"JAMA"},{"key":"B33","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S2213-2600(22)00059-5","article-title":"Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis","volume":"10","author":"Ling","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e001957","DOI":"10.1136\/openhrt-2021-001957","article-title":"Acute myocarditis caused by COVID-19 disease and following COVID-19 vaccination","volume":"9","author":"Kornowski","year":"2022","journal-title":"Open Heart"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1161\/CIRCRESAHA.123.321878","article-title":"COVID-19, myocarditis and pericarditis","volume":"132","author":"Fairweather","year":"2023","journal-title":"Circ Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"951314","DOI":"10.3389\/fcvm.2022.951314","article-title":"Myocarditis in SARS-CoV-2 infection vs. COVID-19 vaccination: a systematic review and meta-analysis","volume":"9","author":"Voleti","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1056\/NEJMc2109975","article-title":"Myocarditis after COVID-19 mRNA vaccination","volume":"385","author":"Verma","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0118283","DOI":"10.1371\/journal.pone.0118283","article-title":"A prospective study of the incidence of myocarditis\/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination","volume":"10","author":"Engler","year":"2015","journal-title":"PLoS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1001\/jamacardio.2021.2833","article-title":"Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military","volume":"6","author":"Montgomery","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2042098620938595","DOI":"10.1177\/2042098620938595","article-title":"Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future","volume":"11","author":"Alomar","year":"2020","journal-title":"Ther Adv Drug Saf"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.07.005","article-title":"Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting","volume":"123","author":"Mascolo","year":"2017","journal-title":"Pharmacol Res"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1210007\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T08:26:33Z","timestamp":1700814393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1210007\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":41,"alternative-id":["10.3389\/fcvm.2023.1210007"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1210007","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]},"article-number":"1210007"}}